Cargando…
Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis
The use of TNF-alpha antagonists (infliximab, etanercept, adalimumab) has changed the course of many rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety including infections have been observed. The aim of the study was to evaluate the c...
Autores principales: | Benucci, M, Saviola, G, Baiardi, P, Manfredi, M, Sarzi Puttini, P, Atzeni, Fabiola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362853/ https://www.ncbi.nlm.nih.gov/pubmed/22655000 http://dx.doi.org/10.2174/1874312901206010033 |
Ejemplares similares
-
No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis
por: Benucci, Maurizio, et al.
Publicado: (2013) -
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2013) -
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
por: Benucci, Maurizio, et al.
Publicado: (2011) -
Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins
por: Benucci, Maurizio, et al.
Publicado: (2015) -
Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment
por: Atzeni, Fabiola, et al.
Publicado: (2019)